

Government of Pakistan  
Ministry of National Health Services, Regulations and Coordination  
(Drug Regulatory Authority of Pakistan)

\*\*\*\*\*

Islamabad, the 3<sup>rd</sup> September, 2021.

NOTIFICATION

S.R.O. 1117 (I)/2021. In exercise of the powers conferred by clause (a) of section 7 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012) read with section 12 of the Drugs Act, 1976 (XXXI of 1976), the Drug Regulatory Authority of Pakistan with the approval of the Federal Government is pleased to direct that in its Notification:-

- (a) No. S.R.O. 708(I)/2018, dated the 6<sup>th</sup> June, 2018, in the Table, in column (1), against serial number 17, for the entry in column (2), the following expression shall be substituted, namely:-

**“Azarga Eye Drop Suspension**  
Each ml of suspension contains:-  
Brinzolamide.....10mg  
Timolol (as timolol maleate).....5mg”;


- (b) No. S.R.O. 1608(I)/2018, dated the 31<sup>st</sup> December, 2018, in the Table, in column (1), against serial number 5, for the entry in column (2), the following expression shall be substituted, namely:-

**“Ryzodeg Solution for Injection**  
Each ml solution contains:  
Insulin degludec/ Insulin aspart in the ratio of 70/30...100 units  
(equivalent to 2.56mg insulin degludec and 1.05mg insulin aspart)”; and

- (c) No. S.R.O. 1096(I)/2020, dated the 21<sup>st</sup> October, 2020, in the Table, in column (1), against serial number 56, for the entry in column (2), the following expression shall be substituted, namely:-

**“Nitroglycerine Injection**  
Each ml contains: -  
Nitroglycerine.....1mg”.

[No. F.11-12/2021-DD(P)]

  
**AAMAR LATH,**  
Deputy Director (Legal Affairs).

**The Manager,**  
Printing Corporation of Pakistan Press,  
Islamabad.